JP7623281B2 - 免疫療法で治療されたがん患者の応答の予測を改善する方法 - Google Patents

免疫療法で治療されたがん患者の応答の予測を改善する方法 Download PDF

Info

Publication number
JP7623281B2
JP7623281B2 JP2021526801A JP2021526801A JP7623281B2 JP 7623281 B2 JP7623281 B2 JP 7623281B2 JP 2021526801 A JP2021526801 A JP 2021526801A JP 2021526801 A JP2021526801 A JP 2021526801A JP 7623281 B2 JP7623281 B2 JP 7623281B2
Authority
JP
Japan
Prior art keywords
hla
cancer
loh
sample
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021526801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513068A (ja
JP2022513068A5 (https=
Inventor
ニコラス シー． ドラコポリ
グスタボ セルケイラ
Original Assignee
パーソナル ゲノム ダイアグノスティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パーソナル ゲノム ダイアグノスティクス インコーポレイテッド filed Critical パーソナル ゲノム ダイアグノスティクス インコーポレイテッド
Publication of JP2022513068A publication Critical patent/JP2022513068A/ja
Publication of JP2022513068A5 publication Critical patent/JP2022513068A5/ja
Priority to JP2024168315A priority Critical patent/JP2025000809A/ja
Application granted granted Critical
Publication of JP7623281B2 publication Critical patent/JP7623281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021526801A 2018-11-15 2019-11-15 免疫療法で治療されたがん患者の応答の予測を改善する方法 Active JP7623281B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024168315A JP2025000809A (ja) 2018-11-15 2024-09-27 免疫療法で治療されたがん患者の応答の予測を改善する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767979P 2018-11-15 2018-11-15
US62/767,979 2018-11-15
PCT/US2019/061710 WO2020102674A1 (en) 2018-11-15 2019-11-15 Method of improving prediction of response for cancer patients treated with immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024168315A Division JP2025000809A (ja) 2018-11-15 2024-09-27 免疫療法で治療されたがん患者の応答の予測を改善する方法

Publications (3)

Publication Number Publication Date
JP2022513068A JP2022513068A (ja) 2022-02-07
JP2022513068A5 JP2022513068A5 (https=) 2024-03-11
JP7623281B2 true JP7623281B2 (ja) 2025-01-28

Family

ID=70727341

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021526801A Active JP7623281B2 (ja) 2018-11-15 2019-11-15 免疫療法で治療されたがん患者の応答の予測を改善する方法
JP2024168315A Pending JP2025000809A (ja) 2018-11-15 2024-09-27 免疫療法で治療されたがん患者の応答の予測を改善する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024168315A Pending JP2025000809A (ja) 2018-11-15 2024-09-27 免疫療法で治療されたがん患者の応答の予測を改善する方法

Country Status (6)

Country Link
US (2) US12497661B2 (https=)
EP (1) EP3880246A4 (https=)
JP (2) JP7623281B2 (https=)
AU (1) AU2019379167A1 (https=)
CA (1) CA3120200A1 (https=)
WO (1) WO2020102674A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230056761A (ko) * 2020-08-26 2023-04-27 리제너론 파마슈티칼스 인코포레이티드 Pd-1 저해제의 투여에 의한 암 치료 방법
CN111979323A (zh) * 2020-08-28 2020-11-24 深圳裕策生物科技有限公司 用于预测肿瘤免疫治疗效果的生物标志物检测方法及系统
CN112029861B (zh) * 2020-09-07 2021-09-21 臻悦生物科技江苏有限公司 基于捕获测序技术的肿瘤突变负荷检测装置及方法
WO2022232503A1 (en) * 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
WO2023196390A1 (en) * 2022-04-06 2023-10-12 Foundation Medicine, Inc. Aneuploidy biomarkers associated with response to anti-cancer therapies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151517A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
WO2017151502A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2018132749A1 (en) 2017-01-13 2018-07-19 The General Hospital Corporation Resistance to checkpoint blockade therapy
WO2018183928A1 (en) 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531279B1 (en) * 1998-04-15 2003-03-11 Genset S.A. Genomic sequence of the 5-lipoxygenase-activating protein (FLAP), polymorphic markers thereof and methods for detection of asthma
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
EP3012329B1 (en) * 2010-06-18 2017-10-25 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
KR20230030022A (ko) * 2014-11-13 2023-03-03 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
CN117467603A (zh) 2015-04-27 2024-01-30 癌症研究技术有限公司 治疗癌症的方法
EP3323070B1 (en) 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
CN114959918A (zh) * 2016-02-29 2022-08-30 基础医疗股份有限公司 用于评估肿瘤突变负荷的方法和系统
US20190247435A1 (en) 2016-06-29 2019-08-15 The Johns Hopkins University Neoantigens as targets for immunotherapy
EP3516081A4 (en) 2016-09-23 2020-07-29 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY
WO2018071796A2 (en) 2016-10-13 2018-04-19 The Johns Hopkins University Compositions and methods for identifying functional anti-tumor t cell responses
CN117987553A (zh) * 2017-09-25 2024-05-07 纪念斯隆凯特琳癌症中心 肿瘤突变负荷和检查点免疫疗法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151517A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
WO2017151502A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2018132749A1 (en) 2017-01-13 2018-07-19 The General Hospital Corporation Resistance to checkpoint blockade therapy
WO2018183928A1 (en) 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor

Also Published As

Publication number Publication date
WO2020102674A1 (en) 2020-05-22
US20200157642A1 (en) 2020-05-21
JP2022513068A (ja) 2022-02-07
EP3880246A4 (en) 2022-08-10
EP3880246A1 (en) 2021-09-22
CA3120200A1 (en) 2020-05-22
AU2019379167A1 (en) 2021-06-03
US12497661B2 (en) 2025-12-16
JP2025000809A (ja) 2025-01-07
US20260071282A1 (en) 2026-03-12

Similar Documents

Publication Publication Date Title
JP7623281B2 (ja) 免疫療法で治療されたがん患者の応答の予測を改善する方法
Díaz-Montero et al. The immunology of renal cell carcinoma
Castelli et al. A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution
Ahn et al. The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression
Biran et al. The genetics of alopecia areata: new approaches, new findings, new treatments
AU2019346023B2 (en) Method for selecting neoepitopes
Pagadala et al. Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response
Klaver et al. Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
KR102770755B1 (ko) 바이러스 네오에피토프 및 이의 용도
KR20190019895A (ko) 네오에피토프의 바이러스 전달을 위한 개선된 조성물 및 방법 및 이의 용도
WO2020221783A1 (en) Methods for pre-selection of neoepitopes
JP2025019066A (ja) 癌の免疫療法のための複合バイオマーカー
Huber et al. Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development
Gong et al. Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy
Dahl et al. The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018
Gillespie et al. Genomic modifiers of natural killer cells, immune responsiveness and lymphoid tissue remodeling together increase host resistance to viral infection
Hou et al. Rational discovery of response biomarkers: candidate prognostic factors and biomarkers for checkpoint inhibitor-based immunotherapy
Zhong et al. The necessary role of an efficient tumor immunotherapy by MHC II expression on amateur APCs
US20220296642A1 (en) Methods of Making Therapeutic T Lymphocytes
JP7626777B2 (ja) マイクロサテライト不安定性シグネチャー
Mohanty et al. Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers
Yan et al. Causal Impact of Immune Phenotypes on Herpes Zoster and Postherpetic Neuralgia: Insights from Mendelian Randomization Analysis
Goli et al. Human Leukocyte Antigen Determinants in Myocarditis and Dilated Cardiomyopathy
Spassova Prognostic and predictive biomarkers in Merkel cell carcinoma
Klaver et al. In contrast to other Soft tissue sarcomas, GIST shows enhanced numbers of immune check-point-negative CD8 T cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220928

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240228

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240927

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241008

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250116

R150 Certificate of patent or registration of utility model

Ref document number: 7623281

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150